BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zainutdinov SS, Kochneva GV, Netesov SV, Chumakov PM, Matveeva OV. Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. Oncolytic Virother 2019;8:9-26. [PMID: 31372363 DOI: 10.2147/OV.S176523] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo D, Wang H, Wang Q, Liang W, Liu B, Xue D, Yang Y, Ma B. Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions. Front Oncol 2022;12:839536. [PMID: 35371972 DOI: 10.3389/fonc.2022.839536] [Reference Citation Analysis]
2 Cristi F, Gutiérrez T, Hitt MM, Shmulevitz M. Genetic Modifications That Expand Oncolytic Virus Potency. Front Mol Biosci 2022;9:831091. [DOI: 10.3389/fmolb.2022.831091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Soleimanjahi H, Heydarabadi FH. Reovirus and Rotaviruses. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00050-1] [Reference Citation Analysis]
4 Rahman MM, McFadden G. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers (Basel) 2021;13:5452. [PMID: 34771615 DOI: 10.3390/cancers13215452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
5 Hazini A, Dieringer B, Klingel K, Pryshliak M, Geisler A, Kobelt D, Daberkow O, Kurreck J, Linthout SV, Fechner H. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. Viruses 2021;13:1918. [PMID: 34696348 DOI: 10.3390/v13101918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu H, Luo H. Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges. Viruses 2021;13:1082. [PMID: 34198859 DOI: 10.3390/v13061082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Al-Zaher A, Domingo-Calap P, Sanjuán R. Experimental virus evolution in cancer cell monolayers, spheroids, and tissue explants. Virus Evol 2021;7:veab045. [PMID: 34040797 DOI: 10.1093/ve/veab045] [Reference Citation Analysis]
8 Rico J, Perez C, Hernandez J, Guerrero C, Acosta O. Cell surface heat shock protein-mediated entry of tumor cell-adapted rotavirus into U-937 cells. Folia Microbiol (Praha) 2021;66:623-38. [PMID: 33950511 DOI: 10.1007/s12223-020-00845-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Monie DD, Bhandarkar AR, Parney IF, Correia C, Sarkaria JN, Vile RG, Li H. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. Neurosurg Focus 2021;50:E10. [PMID: 33524942 DOI: 10.3171/2020.12.FOCUS20855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zaichuk TA, Nechipurenko YD, Adzhubey AA, Onikienko SB, Chereshnev VA, Zainutdinov SS, Kochneva GV, Netesov SV, Matveeva OV. The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector. Mol Biol 2020;:1-15. [PMID: 32921819 DOI: 10.1134/S0026893320060151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
11 Seegers SL, Frasier C, Greene S, Nesmelova IV, Grdzelishvili VZ. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells. J Virol 2020;94:e01643-19. [PMID: 31694943 DOI: 10.1128/JVI.01643-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]